

# FUNGI CAN'T HIDE FROM **Sporanox®** \*

itraconazole 100 mg

One of the notorious problems with fungal infections of the skin or the vagina is that the organism may penetrate the deeper layers of the epithelium, out of reach of topical medication. And besides, when treating fungal skin lesions locally, the infection is often already subclinically present at other sites of the body, waiting for a chance to start the trouble all over again.

Because Sporanox works **orally**, i.e. "from the inside out", it will destroy even the best hidden fungal cells. All the more so, because Sporanox has a strong affinity for epidermal and mucosal tissues as well as for the fungal cell wall itself where it must exert its fungicidal activity.

## SHORT AND SIMPLE ORAL THERAPY

**Standard dose in Dermatology:** 1 capsule (100 mg) once daily for 15 days  
(Sporanox will remain active in the stratum corneum for another 3-4 weeks)

**Standard dose in Gynaecology:** 2 x 2 capsules (400 mg) for 1 day only  
(Sporanox will remain active in the vaginal epithelium for another 3 to 4 days)

This product is not yet available in all countries.

• **Trademarks:** SPORANOX, SEMPERA,  
TRISPORAL, SPORAL.

**Properties:** Sporanox (itraconazole), a triazole derivative, is orally active against infections with dermatophytes (*Trichophyton* spp., *Microsporum* spp., *Epidermophyton floccosum*), yeasts (*Candida* spp., *Pityrosporum* spp.), *Aspergillus* spp. and various other yeasts and fungi. **Indications:** Sporanox (itraconazole) is indicated for vulvovaginal candidosis, pityriasis versicolor, dermatophytoses, fungal keratitis and oral candidosis. **Dosage and administration:** Vulvovaginal candidosis: 2 cap-

sules (200 mg) morning and evening for 1 day, Pityriasis versicolor: 2 capsules (200 mg) once daily for 7 days.

- *Tinea corporis*, *tinea cruris*, *tinea pedis*, *tinea manus*: 1 capsule (100 mg) daily for 15 days; highly keratinized

regions, as in plantar *tinea pedis* and palmar *tinea manus*, require 1 capsule (100 mg) daily for 30 days.

- Oral candidosis: 1 capsule (100 mg) daily for 15 days.

- Fungal keratitis: 2 capsules (200 mg) once daily for 21 days. **Contra-indications:** Sporanox (itraconazole)

is contra-indicated during pregnancy. **Warnings and precautions:** Although clinically Sporanox (itraconazole) has not been associated with hepatic dysfunction, it is

advisable not to give this drug to patients with a known history of liver disease. **Nursing mothers:** It is recommended not to breast feed whilst taking Sporanox (itraconazole). **Drug interactions:** Sporanox (itraconazole) should not be given concomitantly with rifampicin.

Full prescribing information is available on request.

 **JANSSEN**  
PHARMACEUTICA  
2340 Beerse, Belgium  
the drug discovery company

# Essential handbook of vascular diseases

Vascular problems are common – so much so that they are often forgotten and sometimes overlooked – and the incidence of vascular disease has increased to epidemic proportions. But along with this increase has come the rapid development of new methods of diagnosis and treatment. Successful management now requires cooperation among many hospital specialists – vascular surgeons, general surgeons, radiologists, neurologists, cardiologists, orthopaedic surgeons, and general physicians – as well as paramedical staff. A key figure in the equation is the general practitioner, who has a vital part to play throughout. The *ABC of Vascular Diseases* draws together the contributions of all these, condensing years of experience into brief chapters with clear practical messages. Aspects covered include the assessment of severity of disease and medical and radiological treatment as well as surgery. Both early and late complications are covered in detail, making this an essential handbook for everyone concerned in the treatment and rehabilitation of patients with vascular disease.

Published June 1992

UK £12.95; Abroad £15.00  
BMA members £11.95 or £14.00  
including postage, by air abroad

Available from: BRITISH MEDICAL JOURNAL,  
PO Box 295, London WC1H 9TE, medical booksellers  
or the BMJ bookshop in BMA House

Please send me \_\_\_\_\_ copy/ies of

ABC OF VASCULAR DISEASES

I enclose \_\_\_\_\_ Please make cheques payable  
to British Medical Journal

Debit my credit card (please tick box)

Visa  American Express  Mastercard

Card No \_\_\_\_\_

Card expiry date \_\_\_\_\_

Signature \_\_\_\_\_


BMA Membership No \_\_\_\_\_

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

\_\_\_\_\_ POSTCODE \_\_\_\_\_

Please send me a BMJ book catalogue  
Book tokens accepted (UK only)



**“Dr Buxton’s book is a must . . . it is cracking good value”**

GP

Non-specialists overwhelmed by too many systematic descriptions of individual disease will welcome the new approach of the *ABC of Dermatology*. Here the history, clinical appearance, and pathology of a few common key conditions are discussed and then used as a basis for comparison with other skin diseases. Also dealing in detail with allergic reactions, autoimmunity, acne, and infections, this handbook is **fully illustrated in colour**, providing a clear guide to assessment and treatment as well as an understanding of the histological changes underlying the clinical presentations.

“... this little gem is a worthy challenger to all the introductory texts . . .”

Journal of the American Academy of Dermatology

“... extremely good value for money.”

## Contact Dermatitis



“...no hesitation in recommending this book...”

Occupational Medicine

UK £11.95; Abroad £13.50  
BMA members £10.95 or £12.50  
including postage, by air abroad

# ABC OF DERMATOLOGY

PK BUXTON



Available from: BRITISH MEDICAL JOURNAL,  
PO Box 295, London WC1H 9TE, *medical booksellers*  
or the BMT bookshop in BMA House

Please send me \_\_\_\_\_ copy/ies of  
**ABC OF DERMATOLOGY**

I enclose \_\_\_\_\_ Please make cheques payable to **British Medical Journal**

Debit my credit card (please tick box)

Visa  American Express  Mastercard

Card No. -

Card expiry date \_\_\_\_\_

Signature -

BMA Membership No


NAME \_\_\_\_\_

## ADDRESS

POSTCODE

Please send me a book catalogue.

# *Are the ills of middle and later life rooted in our early development?*



During the past few years a series of articles, mostly from the Medical Research Council's Environmental Epidemiology Unit at the University of Southampton, has been published in leading medical journals. They set out the evidence that certain adult diseases, including coronary heart disease, stroke and diabetes originate in impaired development during fetal life and infancy. Because of the obvious implications for prevention of some of the commonest diseases in Western society, they have attracted international attention. In this book, Professor David Barker, Director of the Unit, has selected 31 articles that he considers seminal and a comprehensive guide to the development of this important topic. Professor Roger Robinson's introduction summarises and interprets the evidence for non-epidemiologists.

The first chapters describe the origins of the hypothesis in geographical studies in England and Wales. These are followed by a series of studies of men and women in middle and late life whose early growth was recorded at the time. In those who have died, cause of death can be related to early growth. Examination of the living has allowed blood pressure, blood lipid and insulin concentrations, and other measurements to be related to different patterns of early growth. Together, the findings show that early development affects the risk of coronary heart disease, stroke, obstructive lung disease and diabetes at least as strongly as obesity, smoking and other aspects of adult life style.

***Fetal and Infant Origins of Adult Disease*** brings together in one volume a body of work that cannot be ignored

Hardback • Illustrations • Tables • 368 pages • ISBN 0-7279-0743-3  
UK £24.95; Abroad £30.00 (BMA members £22.95 or £28.00) including postage, by air abroad



## **ORDER FORM**

**British Medical Journal, PO Box 295, London WC1H 9TE.**

Please send me \_\_\_\_\_ copy/ies of **FETAL AND INFANT ORIGINS OF ADULT DISEASE**

NAME \_\_\_\_\_  
(print clearly)

Membership No \_\_\_\_\_

ADDRESS \_\_\_\_\_

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_  
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. \_\_\_\_\_ Exp. \_\_\_\_\_

Signature \_\_\_\_\_

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).

Please send me a book catalogue

POSTCODE \_\_\_\_\_

TRADEMARK

# Prepulsid

## Gets stomach and oesophagus back to work.

### Prepulsid. The force behind G.I. motility.

**Prescribing information** - Prepulsid (cisapride) is a gastro-intestinal prokinetic agent. Prepulsid enhances and co-ordinates gastro-intestinal propulsive motility, thereby preventing stasis and reflux. **Therapeutic indications:** 1. Gastroparesis. 2. Symptoms of X-ray or endoscopy negative upper digestive discomfort. 3. Gastro-oesophageal reflux disorders, including oesophagitis. 4. Intestinal pseudo-obstruction. **Contra-indications:** No absolute contra-indications are known. **Warnings:** Caution should be observed in patients in whom an increase in gastro-intestinal motility could be harmful. **Precautions:** *Pregnancy:* Although, in animals, there is no effect on primary fertility, no primary embryotoxic and no teratogenic effect, the anticipated therapeutic benefits should be weighed against the potential hazards before Prepulsid is given during pregnancy, especially during the first trimester. *Nursing mothers:* Although the excretion in breast milk is minimal, nursing mothers are advised not to breast feed while taking Prepulsid. **Driving and machine-operating ability:** Prepulsid does not affect psychomotor function and does not induce sedation or drowsiness. Prepulsid may, however, accelerate the absorption of central nervous system depressants, such as barbiturates and alcohol. Caution should therefore be exercised when Prepulsid is administered with these drugs. **Interactions:** - The acceleration by Prepulsid of gastric emptying may affect the rate of absorption of drugs: absorption of drugs

from the stomach may be diminished, whereas absorption of drugs from the small bowel may be accelerated (e.g. benzodiazepines, anticoagulants, paracetamol, H<sub>2</sub>-blockers). - In patients receiving anticoagulants, the coagulation times may somewhat increase. It is advisable to check the coagulation time one week after the start of Prepulsid treatment to adapt the anticoagulant dose if necessary. The sedative effects of benzodiazepines and of alcohol may be accelerated. - The effects of Prepulsid on gastro-intestinal motility are, for the most part, antagonized by anticholinergic drugs. - In hepatic and renal insufficiency, it is recommended to halve the initial daily dose. Subsequently, this dose can be adapted, depending on the therapeutic effects or possible side-effects. - In the elderly, steady-state plasma levels are generally higher, due to a moderate prolongation of the elimination half-life. Therapeutic doses, however, are similar to those used in younger patients. - In the case of drugs that require individual titration, it may be useful to monitor plasma levels of such drugs when Prepulsid is associated. **Adverse reactions:** In line with the pharmacological activity of Prepulsid, transient abdominal cramping, borborygmi and diarrhoea may occur. Mild and transient headache or lightheadedness have been reported occasionally. When diarrhoea occurs in babies or infants, the dose should be reduced. There are isolated reports of CNS effects, i.e. convulsive seizures and

extrapyramidal effects. **Dosage:** - Adults: according to the severity of the condition, 15 to 40 mg daily, to be given in 2 to 4 intakes, to be taken as tablets or as oral suspension (the full plastic 5-ml spoon contains 5 mg). As a rule the following doses have proven adequate: • less severe conditions: 5 mg t.i.d. (dose can be doubled); • severe conditions (gastroparesis, oesophagitis, refractory constipation): 10 mg t.i.d. to 10 mg q.i.d. (before the 3 main meals and before retiring). - Infants and children: on the average 0.2 mg/kg per intake, 3 to 4 times daily. For the suspension, intakes are indicated on the dosing pipet as a function of body weight.

**Full prescribing information available on request.**

**Note:** Prepulsid (cisapride) is not yet available in all countries and not all indications have been approved everywhere.

 **JANSSEN**  
PHARMACEUTICA  
B-2340 Beerse, Belgium